Liver cancer patients: which drug works best after immunotherapy?

NCT ID NCT06117891

Ongoing Knowledge-focused Sponsor: Bayer Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jul 08, 2026 · Updated 3 times

Summary

This observational study follows 300 adults with advanced liver cancer that cannot be removed by surgery. All participants have already received a first-line immunotherapy combination (like atezolizumab plus bevacizumab). Researchers will collect data from routine care to see how well different second-line treatments work, focusing on how long patients live and how long their cancer is controlled. No extra visits or tests are required.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this study could help doctors choose the best second-line treatments for patients with advanced liver cancer after initial immunotherapy.
What could go wrong: This is an observational study, not a controlled trial, so it cannot prove cause and effect. Results may be influenced by patient differences and real-world variability.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

UNRESECTABLE HEPATOCELLULAR CARCINOMA

Contacts and locations

Locations

Corporal Michael J Crescenz Department Of Veterans Affairs Medical Center

Philadelphia, Pennsylvania, 19104, United States
Einstein Medical Center

Philadelphia, Pennsylvania, 19141, United States
Many Locations

Multiple Locations, Argentina
Many Locations

Multiple Locations, Brazil
Many Locations

Multiple Locations, China
Many Locations

Multiple Locations, Colombia
Many Locations

Multiple Locations, France
Many Locations

Multiple Locations, Greece
Many Locations

Multiple Locations, Italy
Many Locations

Multiple Locations, South Korea
Many Locations

Multiple Locations, Spain
Many Locations

Multiple Locations, Taiwan
Many Locations

Multiple Locations, Thailand
Mercy Medical Center - Medline Healthcare Services LLC

Baltimore, Maryland, 21202, United States
Roswell Park Comprehensive Cancer Center

Buffalo, New York, 14203, United States
University Of Cincinnati Division Of Hematology Oncology - UC Health System

Cincinnati, Ohio, 45219, United States
University of Michigan Health System

Ann Arbor, Michigan, 48109, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.